The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis.

Blood 2007 Jan 28;109(2):465-70. Epub 2006 Sep 28.

Department of Biostatistics, Mayo Clinic, Rochester, MN 55905, USA.

Primary systemic amyloidosis (AL) is an incurable plasma cell disorder. Lenalidomide, especially in conjunction with dexamethasone, is highly active in patients with multiple myeloma. We studied the toxicity and efficacy of lenalidomide in patients with AL. Patients with symptomatic AL, a measurable plasma cell disorder, and adequate hematologic and renal reserve were eligible. Patients received single-agent lenalidomide. If there was no evidence of progression after 3 months or of hematologic response after 3 cycles, dexamethasone was added. Twenty-three patients were enrolled. Thirteen were previously treated. Organ involvement was cardiac (64%), renal (73%), hepatic (23%), and nerve (14%). Within the first 3 cycles of therapy, 10 patients discontinued treatment: 4 early deaths, 3 adverse events, and 3 other causes. With a median follow-up of 17 months, 10 patients responded to treatment. In these patients, responses included 9 hematologic, 4 renal, 2 cardiac, and 2 hepatic. All but one of the responders had dexamethasone added to their treatment program. The most common grade 3 or 4 adverse events at least possibly attributable to lenalidomide were neutropenia (45%), thrombocytopenia (27%), rash (18%), and fatigue (18%). In AL patients, we saw limited activity of single-agent lenalidomide, but significant activity of the combination with dexamethasone, which warrants further investigation.

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2006-07-032987DOI Listing
January 2007
10 Reads

Publication Analysis

Top Keywords

patients
10
single-agent lenalidomide
8
primary systemic
8
plasma cell
8
hematologic renal
8
cell disorder
8
adverse events
8
systemic amyloidosis
8
dexamethasone
5
lenalidomide
5
months patients
4
therapy patients
4
cycles therapy
4
14% cycles
4
patients discontinued
4
patients responded
4
discontinued treatment
4
deaths adverse
4
median follow-up
4
nerve 14%
4

References

(Supplied by CrossRef)

Similar Publications